Last checked at 22 May 2024 09:53
LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades5,263
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,260.00
Bid:
12,260.00
Ask:
12,264.00
Change:
-144.00 (-1.16%)
Spread:
4.00 (0.033%)
Open:
12,334.00
High:
12,362.00
Low:
12,250.00
Prev. Close:
12,404.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.HSBC lifts AstraZeneca target price on haematological cancer forecasts
Mon, 04th Jan 2016 13:01
(ShareCast News) - HSBC has hiked its target price for AstraZeneca shares after the pharmaceutical giant's acquisition of cancer specialist Acerta Pharma a week before Christmas.AstraZeneca revealed it had agreed to acquire a 55% stake in privately-owned Acerta for $2.5bn, with another $1.5bn due upon approval by the US of the take-over target's lead cancer drug acalabrutinib or by end-2018, whichever was soonest.With Acerta's owners having the option to sell the remaining stake to the FTSE 100 company for $3bn, the broker said it assumed this would occur in 2018, as it saw no rationale for the option to be exercised sooner rather than later.Acalabrutinib, aka ACP-196, could prove to be "best-in-class" monotherapy, the bank said.Phase II clinical data and ongoing phase III trials also meant that acalabrutinib was likely to be very competitive versus Johnson & Johnson and AbbVie's Imbruvica, currently the only drug on the market that inhibits the BTK enzyme and can treat haematological cancers.Shift towards combination therapies justifies price tagAstraZeneca has already signed a wide-ranging collaboration with Celgene to jointly develop immuno-oncology treatments for haematological cancers.Hence, "were the standard of care in some haematological cancers to move to the combination of a BTK inhibitor (such as acalabrutinib) and an anti-PDL1 (such as AstraZeneca's durvalumab), then by acquiring Acerta, AstraZeneca would gain two thirds of the overall economics of the combination (versus 30-50% of durvalumab monotherapy)," the analysts wrote."In our view, that helps justify the potential $7bn price tag for acquiring a company whose main asset has not yet been approved, not even completed phase III development."Despite including revenues from this and other recent acquisitions, 2023 revenue forecasts of circa $37bn were still around $8bn shy of AstraZeneca's 2023 target announced during the failed Pfizer bid process, the analysts noted, though this was increasingly likely to be seen as an aspirational target that diminishes in relevance through time.AZN's target price was lifted to 4,910p from the previous 4,770p, with a 'buy' rating reiterated.
More News
22 May 2024 02:00
British firms expecting hard time in China market, lobby group warns
BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.
Read more21 May 2024 19:00
Sector movers: Stocks slip amid light profit-taking
(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.
Read more21 May 2024 17:20
Europe's STOXX 600 ends lower as rate uncertainty prevails
Focus on Fed minutes, Nvidia earnings
*Read more21 May 2024 17:04
LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading
(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.
Read more21 May 2024 15:00
London close: Stocks fall ahead of key inflation reading
(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.
Read more21 May 2024 12:03
CORRECT: Stocks fall but pound up as IMF ups UK forecast
(Correcting London Stock Exchange index prices.)
Read more21 May 2024 12:00
LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast
(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.
Read more21 May 2024 11:23
AstraZeneca aims for $80 bln in total revenue by 2030
Sees $80 bln in 2030 revenue by 2030
*Read more21 May 2024 09:04
LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall
(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.
Read more21 May 2024 08:18
TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim
(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."
Read more21 May 2024 07:52
LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident
(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.
Read more21 May 2024 07:34
AstraZeneca lays out plans to hit $80bn in revenues by 2030
(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.
Read more20 May 2024 11:55
LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes
(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.
Read more20 May 2024 08:56
AstraZeneca to build $1.5-bln cancer drug plant in Singapore
Plans to build ADCs manufacturing facility in Singapore
*Read more